CorMedix/$CRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CorMedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Ticker
$CRMD
Sector
Primary listing
Employees
191
Headquarters
Website
CorMedix Metrics
BasicAdvanced
$616m
3.70
$2.12
1.46
-
Price and volume
Market cap
$616m
Beta
1.46
52-week high
$14.96
52-week low
$6.13
Average daily volume
1.6m
Financial strength
Current ratio
2.975
Quick ratio
2.585
Long term debt to equity
33.73
Total debt to equity
33.73
Interest coverage (TTM)
73.28%
Profitability
EBITDA (TTM)
228.805
Gross margin (TTM)
91.86%
Net profit margin (TTM)
45.25%
Operating margin (TTM)
50.96%
Effective tax rate (TTM)
2.16%
Revenue per employee (TTM)
$2,090,000
Management effectiveness
Return on assets (TTM)
26.40%
Return on equity (TTM)
65.59%
Valuation
Price to earnings (TTM)
3.703
Price to revenue (TTM)
1.483
Price to book
1.41
Price to tangible book (TTM)
16.08
Price to free cash flow (TTM)
3.048
Free cash flow yield (TTM)
32.81%
Free cash flow per share (TTM)
2.576
Growth
Revenue change (TTM)
384.60%
Earnings per share change (TTM)
651.93%
3-year revenue growth (CAGR)
1,806.05%
10-year revenue growth (CAGR)
111.79%
3-year earnings per share growth (CAGR)
38.39%
10-year earnings per share growth (CAGR)
-1.42%
What the Analysts think about CorMedix
Analyst ratings (Buy, Hold, Sell) for CorMedix stock.
CorMedix Financial Performance
Revenues and expenses
CorMedix Earnings Performance
Company profitability
CorMedix News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs